BACKGROUND
• Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by intensely pruritic eczematous lesions 1,2 • Itch has a significant impact on quality of life (QoL) in children and adults, and it is one of the most important aspects of the disease that patients use to judge treatment response 3,4 • Corticosteroids and calcineurin inhibitors are recommended for topical treatment of AD [5] [6] [7] ; however, there is a need for new, effective, nonsteroidal treatments that address inflammation and itch without the potential limitations associated with current topical agents • Crisaborole ointment is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate AD 8 -In 2 identically designed Phase 3 clinical studies (AD-301: NCT02118766; AD-302: NCT02118792), crisaborole ointment, 2%, significantly improved global disease severity and all measured signs and symptoms of AD, and did not result in any treatment-related serious treatment-emergent adverse events 8
• 
METHODS

Study Treatment
• In the Phase 3 studies, patients aged ≥2 years were randomly assigned in a 2:1 ratio to receive crisaborole or vehicle ointment • Treatment was applied twice daily for 28 days • QoL was measured using the DLQI in patients aged ≥16 years and the CDLQI in patients aged 2-15 years ( Table 1) 13, 14 
Pruritus Scale and Mediation Modeling
• Mediation in its simplest form is represented by a third variable (M, the mediator), so that the predictor X influences the mediator M, which, in turn, influences the outcome Y (X affects M and then M affects Y) (Figure 1 • Severity of pruritus was assessed using the SPS ( Table 2) -SPS was administered via electronic diary twice a day (morning and evening, with a recall period of 24 hours) • All available data were used, and no imputations of missing data were performed
RESULTS
Patients Demographics and Disposition
• Between both studies, 1016 patients were randomly assigned to receive crisaborole and 506 patients were randomly assigned to receive vehicle (intent-to-treat population) • Baseline demographics and disease characteristics were balanced between the treatment arms -The mean age between both groups was approximately 12.2 years; most patients (>86%) were 2-17 years of age -Approximately 55.6% were female; most (80%) were non-Hispanic -Between both groups, distribution by race was approximately 61% white, 28% black, 5% Asian, and 6% other -Baseline disease characteristics are summarized in Table 3 
Mediation Models
• 226 patients were included in the DLQI analysis, and 1112 patients were included in the CDLQI analysis • The indirect effect of crisaborole on QoL via pruritus constituted 51% of the overall effect of active treatment (P = 0.0272) in the DLQI-based model and 72% in the CDLQI-based model (P < 0.0001) (Figures 2, 3 
CONCLUSIONS
• Mediation modeling can be used to help explain the effect of a treatment on an outcome • The presented mediation models indicate that crisaborole affects QoL mostly indirectly through improvement in the severity of pruritus • Indirect effects in the CDLQI-based model were more pronounced, possibly because of differences in item composition of the questionnaires; for example, CDLQI includes sleep, which is highly affected by pruritus
